Financial Performance - Sales to customers for Q1 2024 reached $21,383 million, a 2.3% increase from $20,894 million in Q1 2023[1] - Gross profit for Q1 2024 was $14,872 million, representing a gross margin of 69.6%, up from 68.0% in Q1 2023[1] - Net earnings from continuing operations for Q1 2024 were $3,255 million, compared to a loss of $491 million in Q1 2023[1] - Adjusted net earnings from continuing operations after tax for Q1 2024 were $6,580 million, an increase from $6,340 million in Q1 2023[3] - Net earnings per share (diluted) from continuing operations for Q1 2024 was $2.71, up 12.4% from $2.41 in Q1 2023[3] Expenses - Research and development expenses for Q1 2024 totaled $3,542 million, a 2.5% increase from $3,455 million in Q1 2023[1] - Selling, marketing, and administrative expenses increased to $5,257 million in Q1 2024, up 7.2% from $4,906 million in Q1 2023[1] - Restructuring expenses for Q1 2024 were $164 million, compared to $130 million in Q1 2023[1] - Selling, marketing, and administrative expenses for Q1 2024 were $5,257 million, slightly down from $5,340 million in Q1 2023[6] - The company reported a litigation-related expense of $2,726 million in Q1 2024, consistent with the $6,900 million reported in Q1 2023[8] Taxation - The effective tax rate from continuing operations for Q1 2024 was 12.4%, significantly lower than 61.8% in Q1 2023[1] - The provision for taxes on income in Q1 2024 was $459 million, compared to a benefit of $796 million in Q1 2023[6] Restructuring - The company initiated a restructuring program in its Orthopaedics franchise to streamline operations, resulting in $27 million in restructuring expenses in Q1 2024[4] - The company incurred restructuring costs of $164 million in Q1 2024, compared to $130 million in Q1 2023[6] Research and Development - The adjusted research and development expense as a percentage of sales for Q1 2024 was 21.4%, compared to 16.6% in Q1 2023[8] - Research and development expenses for Q1 2024 totaled $3,542 million, representing an increase from $3,455 million in Q1 2023[6] Profitability Metrics - Adjusted income before tax from continuing operations for Q1 2024 was $5,812 million, up from $5,753 million in Q1 2023, reflecting a growth of 1.0%[8] - The percentage of income before tax from continuing operations to sales for Q1 2024 was 36.6%, compared to 32.8% in Q1 2023[8] - The cost of products sold in Q1 2024 was $6,511 million, down from $6,687 million in Q1 2023, indicating a decrease of approximately 2.6%[6]

Johnson & Johnson baby powder is displayed in San Anselmo, California, on April 5, 2023.Johnson & Johnson on Wednesday said it will pay $6.5 billion to resolve nearly all lawsuits in the U.S. claiming its talc-based products caused ovarian cancer.This story is developing. Please check back for updates. ...

Key PointsThe first quarter of 2024 is coming to a wrap, showing investors where the most prominent Wall Street investors find opportunities to allocate funds. Three stocks became targets for investors like Buffett, Dalio, and Burry. Each has its own merit for being considered. Far from blindly following these pros, investors can see why these stocks are still potential additions in the coming cycle.5 stocks we like better than HSBCWhen the biggest names on Wall Street make an investment decision, the world ...

Core Viewpoint - Johnson & Johnson is positioned as a highly reliable dividend stock, supported by strong cash flow and a robust balance sheet, making it an attractive option for income-seeking investors [1]. Financial Strength - Johnson & Johnson holds a AAA bond rating from multiple credit agencies, indicating a superior capacity to meet financial obligations, even better than the U.S. federal government [2]. - The company ended the first quarter with $26 billion in cash and marketable securities against $34 billion in debt, resulting in a net debt of only $7 billion and a low leverage ratio [2]. - In the previous year, Johnson & Johnson generated $18 billion in free cash flow, which was sufficient to cover its net debt twice over [2]. Dividend Sustainability - The company produced $18 billion in excess cash after investing $15.1 billion in R&D, easily covering its dividend outlay of $11.8 billion and allowing for $2.5 billion in stock repurchases [3]. - Johnson & Johnson raised its dividend by 4.2% earlier this year, marking the 62nd consecutive year of dividend increases, placing it among the elite Dividend Kings [4]. Dividend Yield Comparison - Johnson & Johnson's current dividend yield stands at 3.4%, significantly higher than the S&P 500's yield of 1.4%, providing $34 in annual dividend income for every $1,000 invested compared to $14 from the S&P 500 [5]. - The company anticipates operational sales growth of 5% to 7% annually through 2030, which is expected to drive adjusted operational earnings-per-share growth of over 7% annually [5]. Investment Flexibility - Johnson & Johnson's strong balance sheet and free cash flow allow for continued investments in R&D and acquisitions, enhancing its earnings and dividend growth potential [6].

These healthcare stocks can provide enviable long-term portfolio growth.The healthcare industry has proven to be particularly resilient to the ebb and tide of market sentiment through the years. While stock performance is individual to each company and its own unique growth story, there's a reason these businesses generally stay the course even when overall macro conditions are suffering.Broadly speaking, healthcare companies provide products and solutions that people need no matter what is happening with t ...

Is this top healthcare stock worth adding to your portfolio today?Johnson & Johnson (JNJ -0.46%) is an iconic name in healthcare, with a history that goes back to the 1800s. But in recent years it has faced some considerable challenges, namely to do with lawsuits and the legal battles it faces with respect to its talc products. And today it's a leaner company after having spun off its consumer health business.But the market still appears concerned -- shares of Johnson & Johnson are down 8% in the past 12 mo ...

PM Images The first quarter has come to a close! We are pumped up to share our March dividend income summary. My wife and I earned almost $5,000 in passive income this month. In this article, we will break down the dividend income received, the individual breakdown, and share how much of the income came from individual stocks and mutual funds or ETFs. Why I Invest in Dividend Stocks I invest in dividend stocks to grow my passive income with dividend income. One day, my dividend income will be large enough ...

ToplineAn Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies’ talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company’s latest legal issue involving talc products.Friday’s ruling in Illinois came a day after a judge in Florida rejected similar claims. Getty Images Key FactsTheresa Garcia died in July 2020 after being diagnosed with mesothelioma, a ...

With continued volatility in the stock market right now, it’s no wonder investors are looking for stocks with proven track records to bolster their portfolios. While U.S. stocks opened strong on Monday after a concerning ending to the prior week, investors are still uneasy about the current state of the market. Tensions in the Middle East, concerns that the Federal Reserve may not reduce interest rates as fast as previously hoped and fears over continued inflation are still top of mind for many investors ri ...

Johnson & Johnson (J&J) has emphasized the pivotal role of medical technology (MedTech) in advancing healthcare.During a Tuesday (April 16) call with analysts to discuss the first quarter (Q1) and full-year 2023 financial results, the pharmaceutical giant underscored its commitment to bolstering its reputation as an “innovation powerhouse.” A significant move in this direction is the acquisition of Shockwave Medical, with an enterprise value of approximately $13.1 billion. According to the company, the purc ...